Diagnosis & Disease Information

Decitabine Improves Responses Rates in Elderly Patients with AML

(ChemotherapyAdvisor) – One of the largest randomized phase 3 trials to date in patients ≥65 years of age with newly diagnosed acute myeloid leukemia (AML) has found that decitabine improved response rates compared with low-dose cytarabine or supportive care and had a possible survival advantage, according to results published in the Journal of Clinical Oncology…

Next post in Hematologic Cancers